Managing Refractory Chronic Urticaria in Elderly Patients

Comprehensive Management of Refractory Chronic Urticaria in an Elderly Patient with Multiple Comorbidities: A Case-Based Review for Medical Graduates

1. Introduction: The Multifaceted Challenge of Chronic Urticaria

Chronic urticaria (CU), commonly known as hives, represents a significant dermatological challenge characterized by the persistent recurrence of itchy welts (weals) and/or deeper tissue swelling (angioedema) for a duration exceeding six weeks. This condition profoundly impacts a patient’s quality of life, disrupting sleep, limiting daily activities, and affecting social interactions. The burden of CU can be comparable to, or even surpass, that of severe eczema or coronary heart disease. The case presented involves a patient whose urticaria has proven unresponsive to multiple conventional treatments, underscoring the chronic and refractory nature of their condition.

Managing chronic urticaria becomes particularly intricate in elderly patients with a complex array of co-existing medical conditions. Age-related physiological changes can alter drug pharmacokinetics and pharmacodynamics, while the necessity of multiple medications (polypharmacy) heightens the risk of adverse drug-drug interactions. Furthermore, the cumulative impact of chronic diseases such as cardiovascular issues, metabolic disorders, and mental health challenges can significantly complicate diagnostic processes, therapeutic choices, and overall patient care. The patient, aged 72 years, presents with an extensive medical history including hypertension, type 2 diabetes, migraine, masked depression, gastroesophageal reflux disease (GERD), drug-induced gastropathy, benign prostatic hyperplasia (BPH), renal impairment, and a past susceptibility to liver enzyme disturbances. This clinical profile exemplifies the intricate interplay of these complicating factors.

This report aims to provide a comprehensive, evidence-based analysis and a highly individualized management strategy for this challenging case. By meticulously dissecting the various clinical elements and integrating current research, this document serves as a valuable educational resource for medical graduates. The objective is to illuminate the diagnostic and therapeutic considerations essential for effectively managing refractory chronic urticaria within the complex landscape of polymorbidity and polypharmacy, while adhering to the clinical constraint of avoiding long-term oral steroids.

2. Clinical Case Presentation: A 72-Year-Old with Persistent Urticaria

The patient is a 72-year-old male in the provided history. Chronic urticaria is observed across all age groups and genders, though it is more frequently diagnosed in women aged 30 to 50 years. The primary diagnosis for this patient is chronic urticaria, which is notable for its persistence and unresponsiveness to a range of previously administered antihistamines and a short course of systemic corticosteroids. This clinical presentation strongly suggests Chronic Spontaneous Urticaria (CSU), a form of chronic urticaria characterized by the daily or near-daily occurrence of itchy weals for over six weeks without any identifiable external physical triggers. The absence of specific physical triggers (e.g., cold, heat, pressure, vibration) that would classify the condition as inducible urticaria further supports a spontaneous origin. This classification is fundamental, as it directs the diagnostic approach, such as ruling out inducible forms, and informs subsequent therapeutic strategies, which differ significantly from those for acute or inducible urticaria.

The patient’s medical history is extensive, encompassing several significant comorbidities:

Hypertension: Currently well-controlled, with an average blood pressure of 130/85 mmHg.
Type 2 Diabetes: Managed effectively with Mixtard 30/70 (22 units in the morning, 34 units in the evening), resulting in a well-controlled HbA1c averaging 6.4% (under 7 dl).
Migraine: A co-existing neurological condition.
Masked Depression: A notable psychological comorbidity.
Gastrointestinal Disease: Diagnosed with GERD and drug-induced gastropathy. The patient has a significant history of continuous proton pump inhibitor (PPI) use (Deslansoprazole 60mg) for the past 30 years.
Benign Prostatic Hyperplasia (BPH): A common condition in older males.
Renal Impairment: Indicated by an estimated glomerular filtration rate (eGFR) below 60 mL/min.
History of Liver Enzyme Issues: Previous medications, Atorvastatin 10mg and Fenoget 67mg, were discontinued due to elevated liver enzymes (Transaminase and SGPT), indicating a past susceptibility to hepatic dysfunction.

The patient’s family history is also noteworthy, with early mortality from cardiovascular and renal causes: the father died at age 62 due to a Myocardial Ischemic Attack, the mother at 54 due to Renal Failure, and a sister at 48 due to Pulmonary Embolism. This familial pattern suggests a potential predisposition to systemic vascular or inflammatory conditions, which could be highly relevant to the patient’s current health profile and the complex nature of their urticaria.

The patient’s current medication regimen includes:

* Valsartan 80mg (antihypertensive)

* Nebivolol 5mg in the morning, 2.5mg in the evening (antihypertensive)

* Itopride 50mg twice before meal (prokinetic for GI issues)

* Tamsulosin 0.4mg at night (for BPH)

* Loratadine 10mg One TDS (for urticaria)

* Deslansoprazole 60mg (for GERD)

The persistent nature of the patient’s urticaria, despite the current regimen of Loratadine 10mg three times daily (30mg total daily dose) and previous trials of Chlorpheniramine, Desloratadine, Levocetirizine, Hydroxyzine palmate, Mebhydrolin, and Fexofenadine, highlights a highly refractory case. Although the current Loratadine dose is three times the standard daily dose, it remains below the maximal four-fold up-dosing recommended in international guidelines (e.g., 40mg daily for Loratadine).

3. Chronic Urticaria: Pathophysiology, Classification, and Prognosis

3.1 Etiology and Clinical Manifestations

Chronic urticaria (CU) is formally defined by the presence of itchy wheals and/or angioedema lasting for more than six weeks. The patient’s prolonged history of symptoms aligns precisely with this definition. The characteristic symptoms of urticaria include red, raised, itchy welts (wheals) that can manifest anywhere on the body, vary in size and shape, and typically resolve within 24 hours. Intense itching, or pruritus, is a predominant feature, often accompanied by a burning sensation. Angioedema, a painful swelling in deeper tissue layers, may also occur, commonly affecting areas such as the eyes, lips, or cheeks.

The underlying cause of chronic urticaria frequently remains elusive, leading to its classification as Chronic Idiopathic Urticaria (CIU) or Chronic Spontaneous Urticaria (CSU) when no specific external trigger can be identified. However, various factors are known to trigger or exacerbate symptoms, including physical stimuli (e.g., heat, cold, sunlight, pressure, vibration), infections (such as Helicobacter pylori), thyroid disease, certain allergies, and even malignancies. Psychological stress and anxiety are also well-documented factors that can worsen chronic hives.

3.2 Autoimmune and Genetic Underpinnings

A significant proportion of CSU cases, approximately half, are believed to stem from an autoimmune mechanism. This involves the production of autoantibodies, particularly functional IgG autoantibodies directed against IgE or its high-affinity receptor FcεRIα, found on mast cells. These autoantibodies induce the activation and degranulation of mast cells and basophils, leading to the release of histamine and other inflammatory mediators responsible for the characteristic urticarial symptoms. It is notable that about 20% of individuals with chronic hives also have an associated autoimmune disease, with conditions such as thyroid disease and diabetes frequently observed. The patient’s Type 2 Diabetes, an established autoimmune condition, increases the probability that their chronic urticaria also has an autoimmune basis. This underlying autoimmune component could explain why conventional antihistamines have been ineffective, suggesting the need to investigate specific autoimmune markers (e.g., autologous serum skin test, autoantibodies to IgE or FcεRI) to guide the selection of more targeted advanced therapies.

Genetic predispositions are increasingly recognized as contributing factors in the pathogenesis of CU. Studies have shown an increased prevalence of the disorder among first-degree relatives, indicating a potential hereditary component. Current research is investigating genetic polymorphisms that affect histamine metabolism and mast cell activation pathways. The patient’s strong familial history of early mortality from cardiovascular and renal diseases, conditions often linked to underlying inflammatory or vascular dysfunction, suggests a broader genetic susceptibility to systemic inflammatory processes within the family. This inherited predisposition could contribute to the patient’s complex comorbidity profile and potentially influence the severity and persistence of their urticaria, making it a more challenging and atypical presentation.

3.3 Disease Course and Remission Potential

Chronic Spontaneous Urticaria (CSU) is generally considered a self-limiting condition, though its severity and duration are highly variable. The average disease duration is estimated to be around five years, but symptoms can persist for much longer, even decades, in severe cases. Spontaneous remission of CSU can occur independently of specific treatments. Cumulative remission rates reported in various studies show considerable variability, ranging from 9-38% within the first year, 29-71% by year five, and extending to 52-93% at 20 years. Clinical remission is formally defined as the complete resolution of urticaria signs and symptoms without the need for pharmacotherapy for a minimum of six months. While H1-antihistamines form the cornerstone of treatment for symptom control, they primarily manage the condition rather than offering a permanent cure. Long-term systemic corticosteroids are generally not recommended due to their inevitable and potentially serious adverse effects, although some studies suggest that low-dose oral prednisolone administered for several months might achieve effective clearance and sustained response in certain autoimmune CU cases.

4. Evaluation of Antihistamine Therapy in Refractory Urticaria

4.1 First-Generation Antihistamines

Older, first-generation antihistamines, including Chlorpheniramine, Hydroxyzine, and Mebhydrolin, are effective in treating urticaria due to their H1-receptor antagonist properties. However, their significant sedative and anticholinergic side effects, such as drowsiness, dry mouth, blurred vision, and urinary retention, severely limit their clinical utility, particularly in elderly patients. These agents are short-acting, can impair cognitive function, disrupt sleep, and interfere with daily performance. They also carry risks of interaction with alcohol and other medications.

The patient’s history includes the use of Chlorpheniramine, Hydroxyzine palmate, and Mebhydrolin. The fact that the urticaria remains uncontrolled despite their use, coupled with the patient’s age (72 years) and comorbidities such as masked depression and BPH, strongly indicates that these agents are unsuitable. Their use likely contributed to adverse effects without achieving therapeutic benefit. The use of first-generation antihistamines in this elderly, polymorbid patient presents an unfavorable risk-benefit profile. Their sedative and anticholinergic properties are particularly problematic in older individuals, potentially exacerbating masked depression, increasing the risk of falls, and worsening BPH symptoms. Given their documented failure to control the urticaria, combined with these significant risks, their complete discontinuation from the patient’s regimen is imperative.

4.2 Second-Generation Antihistamines

Second-generation H1-antihistamines (sgH1As) are the recommended first-line treatment for chronic urticaria due to their efficacy and reduced sedative profile compared to first-generation agents. For patients who do not respond adequately to standard doses, international guidelines (EAACI/GA²LEN/EDF/WAO) advocate for increasing the dose up to four-fold. Up-dosing a single antihistamine is generally preferred over combining different antihistamines.

Efficacy Profiles of Specific Agents:

* Loratadine: An effective second-generation antihistamine for CIU, typically dosed at 10mg once daily. Higher doses, up to 40mg daily (e.g., 20mg twice daily), may be used for inadequate symptom control. Dose adjustments are necessary for patients with renal and hepatic impairment (typically 10mg every other day).

* Desloratadine: A rapid-acting, once-daily, non-sedating selective H1-receptor antagonist. Clinical studies demonstrate its efficacy in CIU, significantly reducing pruritus and the number and size of hives, and improving quality of life. It exhibits a higher H1 receptor-binding affinity than its parent compound, loratadine.

* Levocetirizine: Proven effective and well-tolerated in treating chronic idiopathic urticaria symptoms and improving quality of life. Some studies suggest it may be superior to loratadine. It has shown effectiveness for complete suppression of urticaria at 5mg in the intermediate term and 20mg in the short term. It is associated with a lesser degree of somnolence compared to cetirizine.

* Fexofenadine: Demonstrates good tolerability and is statistically superior to placebo in reducing CIU signs and symptoms, with doses of 60mg twice daily or greater being most effective. Up-dosing to 360mg or even 540mg daily has shown effective control in a majority of patients with minimal central nervous system (CNS) side effects. It is recognized for being devoid of sedative and anticholinergic effects.

The patient is currently taking Loratadine 10mg three times daily (30mg daily). While this is a higher dose than the standard 10mg daily, it remains below the maximal four-fold up-dosing (40mg daily) recommended by international guidelines for some second-generation antihistamines. The patient’s history states that “All above drugs are used but Patient does not respond,” which includes Desloratadine, Levocetirizine, and Fexofenadine. This indicates that the patient’s urticaria is profoundly antihistamine-refractory, suggesting a need to consider therapies beyond this class of drugs, or at least ensure maximal optimization has been achieved. Before escalating to more aggressive therapies, it is crucial to confirm that a single second-generation antihistamine (e.g., Loratadine, Fexofenadine, or Levocetirizine) has been tried at its maximally tolerated and guideline-recommended up-dosed level (up to four times the standard dose) for an adequate duration. This step ensures that the first-line treatment strategy has been fully exhausted, which is a critical prerequisite according to international guidelines for defining antihistamine-refractoriness and justifying advanced therapies.

Table 1: Comparative Efficacy and Side Effects of Antihistamines Used by Patient

This table provides a systematic comparison of the pharmacological properties, recommended dosing, and side effect profiles of all antihistamines the patient has reportedly used. It visually emphasizes the significant sedative and anticholinergic side effects of first-generation antihistamines, justifying their discontinuation in an elderly patient with multiple comorbidities. By including the “Max Up-Dosed Recommendation,” the table directly addresses whether the patient’s second-generation antihistamine trials reached guideline-recommended maximal doses, which is crucial for determining true refractoriness. For medical graduates, this table serves as an educational tool, summarizing key information about common antihistamines used in urticaria management, their nuances in elderly and comorbid patients, and guiding appropriate prescribing practices.

5. Impact of Comorbidities and Polypharmacy on Urticaria Management

5.1 Systemic Diseases and Urticaria

Hypertension:

Hypertension is significantly associated with an extended duration of chronic idiopathic urticaria. A study found that 74% of patients with hypertension continued to experience CIU after five years, compared to 54% of those without hypertension. This observation suggests that adequate treatment of hypertension may contribute to better urticaria control. The patient’s hypertension is currently well-controlled; however, the presence of this condition itself may contribute to the persistence of urticaria. Therefore, maintaining optimal blood pressure control, beyond merely preventing cardiovascular events, could indirectly influence the course and duration of chronic urticaria. This connection prompts a continuous focus on cardiovascular health as an integral part of the overall strategy to manage refractory urticaria.

Type 2 Diabetes:

Approximately one in five individuals with chronic hives also have an autoimmune disease, including diabetes. A retrospective cohort study indicated a significantly higher risk of chronic spontaneous urticaria development in patients with type 2 diabetes treated with metformin, with a longer cumulative duration of metformin use associated with an increased risk. Skin-related adverse events, including urticaria, have also been reported with newer anti-diabetic drugs such as SGLT2-I and DPP-4 inhibitors. Although the patient is currently on insulin (Mixtard 30/70) and not oral hypoglycemics like metformin or newer agents, the general association between diabetes and chronic urticaria, coupled with the known potential for certain anti-diabetic medications to induce or worsen urticaria, necessitates a careful review of the patient’s entire diabetes management. A rare allergic reaction to insulin components or the underlying inflammatory state associated with diabetes could theoretically contribute to the urticaria. This emphasizes the need for vigilance regarding all medications, even those seemingly unrelated to the skin condition.

Masked Depression:

Chronic urticaria is strongly linked to an increased likelihood of psychiatric comorbidities, with affected patients being more than three times more likely to experience anxiety (OR 3.48) and depression (OR 3.26). Stress and anxiety are well-known factors that can worsen chronic hives. Effective management of mental health issues, including stress-relieving therapies, can improve overall well-being and potentially aid in urticaria control. The patient’s diagnosis of “masked depression” is a critical factor. The strong association between chronic urticaria and depression often involves a bidirectional relationship, where the chronic and distressing skin symptoms can lead to or worsen depression, which in turn can exacerbate urticaria flares. Therefore, addressing the patient’s masked depression is not merely a supportive measure but a crucial therapeutic intervention that can directly impact the severity and control of the urticaria. A psychological evaluation and appropriate management (e.g., therapy, pharmacotherapy if indicated and compatible with other medications) should be an integral part of the holistic treatment plan, aiming to break the cycle of stress-induced flares.

Migraine:

Severe or long-lasting CSU can be associated with systemic symptoms such as headaches. The patient’s specific diagnosis of “migraine” suggests a distinct neurological condition rather than just a headache as a systemic symptom of urticaria. It is important to consider if any current or past migraine treatments could interact with urticaria medications or if the chronic inflammatory state associated with severe urticaria could exacerbate migraine frequency or severity.

GI Disease (GERD, Drug-induced Gastropathy):

Gastrointestinal complaints, particularly GERD, are highly prevalent in patients with chronic spontaneous urticaria. Some studies report a four-fold higher prevalence of GERD in urticaria patients compared to controls. This suggests a potential link, possibly through the “brain-gut-skin axis” or shared inflammatory pathways. The patient’s long-standing GERD and drug-induced gastropathy are significant. Chronic inflammation originating from the gastrointestinal tract, even if managed by PPIs, could contribute to systemic inflammatory mediators that perpetuate the chronic urticaria. This connection suggests that optimizing gastrointestinal health and addressing the root cause of the drug-induced gastropathy are important, not just for GI comfort but for their potential impact on urticaria control.

5.2 Renal and Hepatic Impairment Considerations

Renal Impairment (eGFR < 60):

The patient’s eGFR below 60 mL/min indicates moderate chronic kidney disease. This has significant implications for drug clearance. Many second-generation antihistamines (e.g., loratadine, cetirizine) require dose adjustments (typically reducing frequency to every other day) when GFR is below 30 mL/min. Cyclosporine is contraindicated in impaired kidney function and requires close monitoring and dose adjustments for renal function. Furthermore, chronic kidney disease itself can cause generalized pruritus (uremic pruritus), which is distinct from urticaria but can present as severe itching. This raises the possibility that a portion of the patient’s “uncontrolled urticaria” might actually be uremic pruritus, complicating symptom assessment and treatment response. This necessitates a careful clinical differentiation between urticarial wheals and uremic pruritus and consideration of specific treatments for uremic pruritus if diagnosed, in addition to managing the urticaria. This also highlights the critical need for meticulous medication dose adjustments based on renal function to prevent toxicity and optimize therapeutic effect.

Liver Enzyme History:

The patient’s history of elevated liver enzymes (Transaminase and SGPT) leading to the discontinuation of Atorvastatin and Fenoget indicates a predisposition to hepatic sensitivity. While omalizumab clearance is generally not affected by hepatic impairment, cyclosporine dosing requires careful reduction and monitoring in patients with severe liver impairment. Loratadine also requires dose adjustment in hepatic impairment. Liver problems can also be associated with CSU. This past liver sensitivity significantly restricts the choice of new medications, particularly those with known hepatotoxicity or extensive hepatic metabolism. It necessitates extreme caution and vigilant monitoring of liver function if advanced therapies like cyclosporine are considered, making omalizumab a comparatively safer option in this regard. This also reinforces the need to ensure all current medications are not contributing to liver stress.

5.3 Drug-Induced Urticaria and Interactions

PPIs (Deslansoprazole) as a Potential Trigger:

The patient has been on Deslansoprazole 60mg for 30 years. Proton pump inhibitors (PPIs), including omeprazole and lansoprazole, have been reported to cause hypersensitivity reactions such as urticaria and angioedema in a small percentage of patients (0.5-1.5%). These reactions can be IgE-mediated (Type I hypersensitivity) and can manifest as immediate or non-immediate reactions, with some patients showing cross-reactivity to the entire class of PPIs. This is a critical factor that must be thoroughly investigated. The possibility that the long-term PPI itself is the primary, ongoing cause or a significant exacerbating factor for the urticaria cannot be overlooked. A carefully managed PPI de-challenge or a switch to an alternative acid-suppressing agent (e.g., an H2-receptor antagonist, if clinically appropriate for GERD and gastropathy, noting H2 blockers are not generally recommended for CU ) should be a high-priority diagnostic and therapeutic step. If successful, this could lead to resolution of the urticaria by removing the underlying trigger, rather than simply escalating symptomatic treatment.

Drug-Drug Interactions (General Polypharmacy Risk):

The patient’s extensive medication list includes Valsartan, Nebivolol, Itopride, Tamsulosin, Loratadine, Deslansoprazole, and Mixtard (insulin). Valsartan is known to interact with 308 drugs , Nebivolol with 534 drugs , and their combination has 607 known interactions. Deslansoprazole can interact with cytochrome P450 (CYP) enzymes and may increase levels of tacrolimus (an immunosuppressant similar to cyclosporine). Tamsulosin can have increased systemic exposure when co-administered with CYP2D6 inhibitors (like some first-generation antihistamines the patient previously used). Nebivolol can mask hypoglycemia symptoms in diabetics. Long-term PPI use can also lead to hypomagnesemia and B12 deficiency.

The patient’s extensive medication list, coupled with compromised renal function (eGFR < 60) and a history of liver enzyme disturbances, creates a high-risk environment for cumulative adverse drug reactions and exacerbated side effects. Even if individual interactions are classified as “moderate” or “minor,” their combined effect on already impaired organ systems can be significant. The patient’s “masked depression” could potentially be exacerbated or even partly caused by the cumulative side effects of polypharmacy (e.g., fatigue, cognitive impairment, electrolyte imbalances like hypomagnesemia from PPIs). This highlights the critical need for a thorough medication reconciliation, a detailed review of all potential interactions, and careful monitoring of organ function. Optimizing the medication regimen by discontinuing unnecessary or high-risk drugs (like first-generation antihistamines) and adjusting doses for renal/hepatic function is paramount, as it could indirectly improve urticaria control by reducing systemic stress and improving overall well-being.

Table 2: Patient’s Current Medications: Potential Interactions and Comorbidity Impact

| Nebivolol | Hypertension | 5mg AM, 2.5mg PM | Hepatic (major) / Renal (minor) | Cyclosporine (potential synergistic effect on calcineurin pathway, but direct interaction not clearly defined) ; Valsartan (additive BP lowering) | Renal impairment (disease interaction) ; Liver disease (disease interaction) | Anaphylactic reaction (may increase risk) | Masks hypoglycemia symptoms in diabetics, dizziness, fatigue |

| Itopride | GI Prokinetic | 50mg BID | Hepatic (Flavine monooxygenase) | Anticholinergic drugs (reduced action of itopride) ; Drugs with narrow therapeutic index (absorption influence) | Not specified, but primarily hepatic metabolism suggests caution with liver impairment | Not directly linked to urticaria in snippets | Potential cholinergic side effects |

This table provides a comprehensive, organized reference for all current medications, their indications, and relevant pharmacological details. It clearly maps potential drug-drug interactions, especially those that could affect the efficacy or safety of urticaria treatments or exacerbate existing comorbidities. It explicitly details how each medication’s metabolism and excretion impact the patient’s compromised renal function and history of liver enzyme issues, guiding necessary dose adjustments and monitoring. Crucially, it brings attention to medications like Deslansoprazole that could be directly contributing to the patient’s refractory urticaria, prompting investigation into de-challenge or alternative therapies. This supports clinicians in making informed decisions about medication optimization, risk mitigation, and the selection of new therapies by providing a clear overview of the complex pharmacological landscape.

6. Advanced Therapeutic Approaches for Refractory Chronic Urticaria in Pakistan

6.1 International Guidelines and Local Context

International guidelines, such as those from EAACI/GA²LEN/EDF/WAO, advocate a step-wise approach for Chronic Spontaneous Urticaria (CSU) management. The initial step involves standard doses of second-generation H1-antihistamines. If symptoms persist, the dose should be increased up to four-fold. Should this maximal antihistamine therapy prove ineffective, omalizumab is recommended as the second-line treatment. For patients who do not respond to omalizumab, cyclosporine or leukotriene antagonists are considered as third-line options. Systemic corticosteroids are generally reserved for acute, severe exacerbations and should be used only for short durations (less than one week) due to their significant adverse effects.

In the local context of Pakistan, chronic urticaria is a prevalent health issue. Local research has explored the efficacy of Autologous Serum Therapy (AST) as a potential treatment, with studies suggesting it can be more effective than oral antihistamines in some chronic urticaria patients. AST is thought to work by generating antibodies against mast cell degranulating antigens, such as the high-affinity IgE receptor (anti-FcεRI) or IgE itself (anti-IgE). While broader reviews consider evidence for AST’s potential benefit as low, it is noted for its relatively low cost and good safety profile in the local context. The discrepancy between international guidelines, which prioritize omalizumab as the second-line agent, and local Pakistani studies highlighting autologous serum therapy (AST) as a more effective alternative to antihistamines, underscores the importance of integrating both global evidence-based guidelines and local clinical experience and resource availability into the management plan. While omalizumab is the gold standard, AST might be a more accessible or cost-effective intermediate step in Pakistan, especially given the high cost of biologics. This highlights the need for a pragmatic approach tailored to the patient’s specific circumstances and the healthcare system’s realities.

6.2 Biologic and Immunosuppressive Therapies

Omalizumab (Xolair):

Omalizumab is a humanized monoclonal antibody that specifically targets and binds to free immunoglobulin E (IgE) in the bloodstream. By preventing IgE from binding to its high-affinity receptor (FcεRI) on mast cells and basophils, it reduces circulating free IgE levels and subsequently downregulates FcεRI expression, thereby suppressing mast cell activation and histamine release. This mechanism of action is crucial in controlling urticarial symptoms.

Clinical trials have demonstrated high effectiveness and safety with omalizumab in antihistamine-refractory CSU. Treatment response is dose-dependent, with 300mg given every four weeks showing the highest efficacy. Significant reduction in mean Urticaria Activity Score (UAS7), itch severity, and hive score has been observed as early as week 4, with sustained improvement. Complete clearance (UAS7=0) was achieved in 38% of patients, and partial response (UAS7≤6) in 55.1% in active treatment groups. Omalizumab also significantly improves quality of life. Adverse events are generally mild to moderate, with injection-site reactions being the most common. Anaphylaxis is a known but rare adverse event associated with omalizumab. While no specific dose adjustment is recommended for patients with renal or hepatic impairment due to its clearance mechanism, caution is advised.

Omalizumab has been approved for refractory CSU in Pakistan. However, its high cost (approximately US$600 per 300mg dose) is a significant barrier, potentially restricting its widespread use in resource-limited settings. For instance, a 150mg vial of Xolair costs around PKR 38,000. The need for subcutaneous administration in a hospital setting due to the rare risk of anaphylaxis also adds to the logistical challenges. Despite these challenges, omalizumab remains the gold standard second-line therapy for antihistamine-refractory CSU due to its proven efficacy and safety profile.

Cyclosporine:

Cyclosporine is a powerful immunosuppressant that inhibits both cell-mediated and humoral immune responses. It works by inhibiting the release of histamine from basophils and tumor necrosis factor-alpha (TNF-α) production by mast cells. Numerous reports attest to its efficacy in urticaria, with prolonged treatment potentially beneficial for maintaining remission in severe cases and reducing the need for corticosteroids. The typical dosage ranges from 3-5 mg/kg/day, which is then gradually reduced over several months.

However, cyclosporine carries significant contraindications and side effects. Its main contraindications include impaired kidney function, uncontrolled blood pressure, active serious infections, and cancers. Common adverse effects include renal dysfunction, tremor, hirsutism, hypertension, and gum hyperplasia. Dose adjustments and close monitoring of blood concentrations are necessary in patients with severe liver impairment. Given the patient’s existing renal impairment (eGFR < 60), hypertension, and history of liver enzyme issues, cyclosporine use would necessitate extremely careful consideration and vigilant monitoring of renal function, blood pressure, and liver enzymes. This makes it a less favorable option compared to omalizumab, especially as a second-line treatment.

Other Novel Therapies:

The landscape of CSU treatment is evolving with novel therapies. Bruton’s tyrosine kinase (BTK) inhibitors, such as remibrutinib, are emerging as promising oral treatments for CSU refractory to H1-antihistamines. Remibrutinib, developed by Novartis, is a highly selective oral BTK inhibitor that blocks the BTK cascade, thereby preventing the release of histamine that causes itch, hives, and swelling. Phase III trials (REMIX-1 and REMIX-2) have shown rapid and clinically meaningful improvements in urticaria disease activity scores as early as two weeks after treatment initiation, with a favorable safety profile. If approved, remibrutinib has the potential to become the first new class of oral CSU treatment in a decade, offering a convenient option for patients uncontrolled by antihistamines. However, its current availability in Pakistan is limited to research quantities and is not for patient use.

6.3 Autologous Serum Therapy (AST)

Autologous Serum Therapy (AST) involves injecting the patient’s own serum intramuscularly. This therapy is thought to work by generating antibodies against mast cell degranulating antigens, such as the high-affinity IgE receptor (anti-FcεRI) or IgE itself (anti-IgE). Local studies in Pakistan have investigated AST, suggesting it can be more effective than oral antihistamines in some chronic urticaria patients. For instance, one study found AST to be effective in 76.92% of patients compared to 48.08% for antihistamine therapy. Another study reported significant improvements in both ASST-positive and ASST-negative patients with sustained action. While broader reviews consider evidence for AST’s potential benefit as low, it is noted for its relatively low cost and good safety profile in the local context. AST may be considered as an adjunctive or alternative therapy, particularly if financial constraints or accessibility issues limit biologic use, given local evidence of its efficacy.

7. Proposed Comprehensive Management Plan

The management of this patient’s refractory chronic urticaria necessitates a multi-faceted, individualized, and systematic approach that meticulously addresses the complex interplay of their numerous comorbidities and polypharmacy.

7.1 Re-evaluation and Diagnostic Refinement

* Thorough Clinical History and Physical Examination: A detailed re-evaluation of the patient’s urticaria characteristics, including frequency, severity, duration of individual lesions, and associated angioedema, is essential. A comprehensive review of all medications, both current and past, including over-the-counter drugs and supplements, is critical.

* Laboratory Investigations:

* Baseline and Current Status: Full blood count, Erythrocyte Sedimentation Rate (ESR) or C-reactive protein (CRP) to assess inflammation.

* Organ Function: Re-check current liver enzymes (Transaminase and SGPT) and renal function (eGFR) to establish current status and guide medication adjustments.

* Endocrine and Autoimmune Markers: Thyroid function tests (TSH) to rule out thyroid disease, which is commonly associated with CSU. Given the patient’s Type 2 Diabetes and refractory urticaria, investigations for specific autoimmune markers for CSU should be considered, such as the autologous serum skin test (ASST) and autoantibodies to IgE or FcεRI. These tests can help confirm an autoimmune etiology, which often predicts a poorer response to antihistamines and a better response to therapies like omalizumab or cyclosporine.

* Investigation of Drug-Induced Urticaria: A primary focus must be placed on the patient’s 30-year history of Deslansoprazole use. While PPI-induced urticaria is rare, long-term continuous exposure makes it a highly suspicious ongoing trigger. A carefully managed PPI de-challenge or a switch to an alternative acid-suppressing agent (e.g., an H2-receptor antagonist, if clinically appropriate for GERD and gastropathy) should be a high-priority diagnostic and therapeutic step. This approach aims to identify if the PPI is the primary, ongoing cause or a significant exacerbating factor for the urticaria, potentially leading to resolution by removing the underlying trigger.

7.2 Medication Optimization and De-escalation

* Antihistamines:

* First-Generation Antihistamines: All first-generation antihistamines (Chlorpheniramine, Hydroxyzine palmate, Mebhydrolin) must be immediately discontinued. Their significant sedative and anticholinergic side effects pose an unfavorable risk-benefit profile in this elderly patient, potentially worsening masked depression, increasing fall risk, and exacerbating BPH symptoms, without providing adequate urticaria control.

* Second-Generation Antihistamines: The current Loratadine dose (10mg TDS) is 30mg daily, which is below the maximal four-fold up-dosing (40mg daily) recommended by international guidelines. Before escalating to more aggressive therapies, a single second-generation antihistamine (e.g., Fexofenadine or Levocetirizine, considering their efficacy and generally lower sedation profile) should be maximally up-dosed to four times the standard dose (e.g., Fexofenadine up to 540mg daily , Levocetirizine up to 20mg daily ). This must be done with appropriate dose adjustment for the patient’s renal impairment (e.g., Loratadine/Levocetirizine dose reduction to every other day if GFR < 30 mL/min ). This step ensures that the first-line treatment strategy has been fully exhausted before moving to advanced therapies.

* Comprehensive Polypharmacy Review: A meticulous review of all current medications (Valsartan, Nebivolol, Itopride, Tamsulosin, Mixtard) is essential to identify and minimize potential drug-drug interactions and cumulative side effects. Particular attention should be paid to interactions affecting renal or hepatic function, or those that could exacerbate masked depression (e.g., CNS depressant effects). Dose adjustments for medications excreted renally must be made based on the patient’s eGFR.

7.3 Targeted Advanced Therapies

If maximal antihistamine therapy, including appropriate up-dosing and dose adjustments, fails to control the urticaria after an adequate trial period (e.g., 2-4 weeks), advanced therapies should be considered.

* Omalizumab (Xolair): This should be the preferred second-line agent. Its mechanism of action (IgE neutralization) is highly targeted, and it generally has a favorable safety profile with no specific dose adjustments needed for renal or hepatic impairment. While cost is a significant factor in Pakistan , its efficacy and safety in antihistamine-refractory CSU are well-established. A discussion with the patient and family regarding the financial implications and administration logistics (subcutaneous injections, potentially in a hospital setting for initial doses due to rare anaphylaxis risk) is crucial.

* Cyclosporine: This agent should be reserved as a third-line option if omalizumab is ineffective, not tolerated, or not feasible. Its use in this patient requires extreme caution due to existing renal impairment, hypertension, and a history of liver enzyme issues. Cyclosporine is contraindicated in impaired kidney function and uncontrolled blood pressure, and requires careful dose reduction and vigilant monitoring of renal function, blood pressure, and liver enzymes. The risks of cumulative toxicity are high in this polymorbid elderly patient.

* Autologous Serum Therapy (AST): Given its reported efficacy in local Pakistani studies and relatively lower cost , AST could be considered as an adjunctive or alternative therapy, particularly if access to biologics like omalizumab is limited by financial or logistical constraints.

7.4 Comorbidity Management

* Masked Depression: A formal psychological assessment is critical. Appropriate management, which may include psychotherapy or antidepressant medication (carefully selected to avoid interactions and considering comorbidities), is essential. Addressing the psychological burden can significantly improve the patient’s quality of life and may indirectly reduce urticaria flares by mitigating stress-induced exacerbations.

* Hypertension and Type 2 Diabetes: Strict and consistent control of blood pressure and blood glucose levels must be maintained. Optimal management of these chronic conditions may indirectly improve the duration and severity of urticaria and contribute to overall patient well-being.

* Renal Impairment: Ongoing meticulous monitoring of renal function is paramount. All medications must be reviewed regularly for appropriate dose adjustments based on eGFR to prevent drug accumulation and toxicity. Furthermore, a careful clinical differentiation between urticarial wheals and uremic pruritus (itching due to chronic kidney disease) is necessary, as uremic pruritus can present as severe itching and may require distinct management.

* Liver Health: Regular monitoring of liver enzymes is crucial, especially if new medications are introduced. Careful selection of new therapies is needed to avoid further hepatic stress, given the patient’s history of drug-induced liver enzyme disturbances.

7.5 Patient Education and Support

Comprehensive patient education is vital. The patient should be informed about the chronic nature of urticaria, potential triggers (including stress and medications), and the importance of strict adherence to the complex treatment plan. Realistic expectations regarding remission and symptom control should be discussed. Empowering the patient with knowledge about their condition and involving them in treatment decisions can significantly improve compliance and overall outcomes.

8. Conclusion and Future Directions

The case of this 72-year-old patient with refractory chronic urticaria, complicated by multiple comorbidities and polypharmacy, highlights the profound challenges in managing such complex clinical presentations. The patient’s persistent symptoms, despite extensive antihistamine trials, point towards Chronic Spontaneous Urticaria, likely with an autoimmune component given the co-existing Type 2 Diabetes. The long-term use of proton pump inhibitors emerges as a critical, potentially overlooked, contributing factor that warrants immediate investigation through a carefully managed de-challenge. Furthermore, the patient’s renal impairment and history of liver enzyme disturbances significantly narrow therapeutic options and necessitate meticulous medication adjustments and vigilant monitoring to prevent adverse drug reactions and cumulative toxicity. The presence of masked depression underscores the bidirectional relationship between chronic skin conditions and mental health, emphasizing the need for integrated psychological support.

Effective management of this atypical clinical condition requires a holistic, individualized, and evidence-based approach. This includes:

* Thorough Diagnostic Re-evaluation: To confirm the CSU diagnosis, identify potential autoimmune markers, and definitively rule out drug-induced urticaria, particularly from the long-term PPI.

* Systematic Medication Optimization: Maximizing second-generation antihistamines to guideline-recommended up-doses while discontinuing first-generation agents and carefully reviewing all current medications for interactions and organ-specific risks.

* Strategic Implementation of Advanced Therapies: Prioritizing omalizumab as the preferred second-line agent due to its targeted mechanism and favorable safety profile, while reserving cyclosporine for specific circumstances with extreme caution and rigorous monitoring. Autologous serum therapy remains a viable, accessible option in the local context.

* Integrated Comorbidity Management: Ensuring strict control of hypertension and diabetes, addressing masked depression, and carefully managing renal and hepatic function to alleviate systemic stressors that may perpetuate urticaria.

This case serves as a valuable educational paradigm for medical graduates, illustrating the necessity of moving beyond symptomatic treatment to a comprehensive understanding of underlying pathophysiological mechanisms, medication interactions, and the profound impact of comorbidities in elderly patients with chronic, refractory conditions. Future research should focus on identifying reliable biomarkers for treatment response in polymorbid elderly patients with CSU and evaluating the long-term outcomes and cost-effectiveness of novel therapies in real-world clinical settings, particularly in resource-constrained environments.

Dr. Jawed Ahmed Qazi | Senior Physician | Almumtaz Medical and Trauma Center Karachi